Second primary breast cancer occurrence according to hormone receptor status
about
Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor statusThe risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study populationRisk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study.Concordance in histological and biological parameters between first and second primary breast cancers.Rate of contralateral prophylactic mastectomy is influenced by preoperative MRI recommendations.Declining incidence of contralateral breast cancer in the United States from 1975 to 2006Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer.PARP Inhibitors for the Treatment and Prevention of Breast Cancer.Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE studyComparative genomic analysis reveals bilateral breast cancers are genetically independentNipple Aspirate Fluid Hormone Concentrations and Breast Cancer RiskPreoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer.Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).Change of mammographic density predicts the risk of contralateral breast cancer--a case-control study.Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen.Bilateral breast cancers.Incidence of metachronous contralateral breast cancer in Denmark 1978-2009.Bilateral mastectomy and the retreat from breast-conserving surgery.Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.A model for individualized risk prediction of contralateral breast cancer.Effects of estrogen on the proportion of stem cells in the breast.Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.Risk of second breast cancer according to estrogen receptor status and family history.Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands.Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.When is contralateral mastectomy warranted in unilateral breast cancer?Lupus antibody tops cancer cells.Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data.History, biology, and health inequities: emergent embodied phenotypes and the illustrative case of the breast cancer estrogen receptor
P2860
Q31120324-D8562EE7-3B7A-4C7C-9E2E-29800A0152B8Q33632366-1ABF4EC0-AF8D-45D1-A5F3-424300C1AAA7Q33739428-8B637D85-0D99-4404-B3E7-4333233652AFQ33901385-C06FAAAF-1B24-4CE5-BF8E-26FB8BF6E747Q33919320-CD91B3C3-0F9E-4CA8-9FA2-68755C21E91EQ33946233-0C6D8DCE-A055-43C6-BD9F-54418795D7A9Q34088422-61CC498B-B7B7-4FE6-9215-1271B01E62B9Q34441602-02B20DF0-21DC-4D3D-8613-CEED38946E1BQ34500780-F8EF6338-3CE3-4790-87A3-E8D25E327B1FQ34629071-C23E9588-3FBE-4C4A-94CF-A4AD019E0564Q34866230-5463C419-7BD7-453E-8120-10C506C73E85Q35000330-6882B7A9-6429-4C4D-BD50-FD60DFE9E817Q35115896-F1E1DC65-359C-4709-86F1-2B64206477A7Q35993616-76A587CE-89A8-4507-A71F-03C15EDFB7C6Q36187913-E87A65A8-FECF-43A9-B440-9EAF4E555DD8Q36298086-C871C757-5E65-4648-846E-E3A818B0058CQ36415317-C91D27C6-8D67-49FE-80BD-8BC26E04EF8FQ36544696-75A96BE7-1164-4B30-A2CA-7C06E477747AQ36728342-61358505-9885-471D-8623-C3BFFC2ABF81Q36914472-156C66B8-8FE5-44DC-BB6E-D0B3962DF9E5Q37117139-AF020074-0427-4D0F-96E1-9408F5CCEB1EQ37122297-D04BCE5B-EBD4-4E2E-8340-624679ED7865Q37267678-0A5A1D33-5CF1-40A4-9638-BABAAD5A433EQ37689779-421EA772-BEDD-45B0-ABCC-9CDD1064B729Q37913359-9C148E31-C3D0-459F-9DDD-035304E75025Q38184906-EEEE5D22-B305-4895-A4CB-52E147DB4122Q38418228-2B9A574C-9EF0-47B3-A5AC-03E6BA33D03CQ38913440-3551EBD5-642A-4091-B353-609996D897B2Q39150355-315ED192-5F67-4AB3-8256-105D1F2E9439Q39213394-6F0807C5-FFD3-4739-9814-923E169B91EAQ39652970-A77EAECB-96CF-4823-BB9B-06EB977AEA01Q40616060-60227882-C87E-44D9-A136-C409D35C24C0Q44558762-EEF80DAD-C50D-45F3-AB0F-532CA820B8CCQ45897710-6EE2CA62-039F-4BE5-83A0-FBFBE19B20C6Q46044304-339C6EE1-5F92-4B08-88A7-93011F250499Q48111239-F895D1F9-8CA2-42EF-B0E9-18D5F5B26ED6Q53137268-A0E59B98-DC5D-4E56-9175-1A3862423EAEQ55515741-521288EA-5ADC-419D-9743-007C0E9B9BF0Q57148481-6D3220C5-F26E-48C1-BDEA-9E0F2F88F5BE
P2860
Second primary breast cancer occurrence according to hormone receptor status
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Second primary breast cancer occurrence according to hormone receptor status
@en
Second primary breast cancer occurrence according to hormone receptor status.
@nl
type
label
Second primary breast cancer occurrence according to hormone receptor status
@en
Second primary breast cancer occurrence according to hormone receptor status.
@nl
prefLabel
Second primary breast cancer occurrence according to hormone receptor status
@en
Second primary breast cancer occurrence according to hormone receptor status.
@nl
P2860
P50
P356
P1476
Second primary breast cancer occurrence according to hormone receptor status
@en
P2093
Allison W Kurian
Laura A McClure
P2860
P304
P356
10.1093/JNCI/DJP181
P407
P577
2009-07-09T00:00:00Z